Court Square, NextDocs provide FDA approved document management
SPRINGFIELD, Mass. Court Square Data Group and NextDocs announced that they are partnering to deliver document management solutions to biotech, pharmaceutical and medical device firms that must comply with Food and Drug Administration regulations.
Court Square will provide hosted-solutions and project management and integration services to NextDocs customers who use its 21 CFR Part 11 compliant document and quality management products.
“NextDocs has developed a powerful family of document and quality management solutions that are specifically designed to meet the needs of biotech, pharmaceutical and other FDA-regulated firms,” said NextDocs chief executive officer Zikria Syed. “We built this application atop the Microsoft SharePoint 2007 platform, ensuring compatibility with the most widely adopted business applications. In addition, we took full advantage of SharePoint’s ability to function as a web portal, enabling NextDocs customers to access and use our software throughout the distributed enterprise.”
Sandoz completes $10 million expansion of N.C. facility
WILSON, N.C. Sandoz recently completed the major phase of its Wilson, North Carolina expansion when over 50 employees moved into a new 30,000 square foot building.
Over 65 new jobs are expected to be created in Wilson as a result of the $10 million expansion. The positions will be filled by pharmaceutical scientists and analytical chemists and will bring the total of employees at the site to almost 480.
“The new laboratories present an excellent workplace and opportunity for top scientists to help us continue to growth in the U.S.,” said Bernhard Hampl, president and chief executive officer of Sandoz. “The new products developed at the site will be the basis for the future growth of the Wilson site.”
Pfizer, Taisho sign letter of intent over schizophrenia drug candidate
TOKYO and NEW YORK Taisho Pharmaceuticals and Pfizer have concluded on a letter of intent with regard to Taisho’s new drug candidate for schizophrenia, TS-032.
The drug is currently in the pre-clinical stage and the letter of intent relates to a proposed license agreement regarding rights for development and commercialization.
Through the agreement, Taisho will grant exclusive development and commercialization rights outside Japan for the drug to Pfizer. Once the agreement is signed, Taisho will receive an initial payment of $22 million as well as milestone and royalties linked to the development and sales of the drug.